Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Lasa Supergenerics Limited is engaged in manufacturing, trading, and producing chemicals, pharmaceuticals, and veterinary APIs, with comprehensive capabilities in research, production, and marketing.
The company specializes in catalyst chemistry and is among India's largest producers of anthelmintic and veterinary API products, with significant production capacity at its facilities in Maharashtra.
Lasa's strategic amalgamation with Harishree Aromatics and Chemicals Pvt. Ltd. strengthens its manufacturing capabilities and market reach, approved by the National Company Law Tribunal in late 2022.
The company has launched two new high-demand veterinary products and is expanding capacity at its Chiplun unit, aiming to capture significant market share globally.
With a WHO Certificate of Good Manufacturing Practices, Lasa is positioned as a key player in the animal healthcare sector with robust global alliances.
Pharmaceuticals & Biotechnology
Pharmaceuticals
34 Cr
Low Risk
-2.0
37.7
—
0.7
14.14
5.65
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q2 FY21
Investor Presentation
Q4 FY20
Investor Presentation
Q4 FY18
Investor Presentation
Q3 FY18
Investor Presentation
Q2 FY18
Lasa Supergenerics Ltd (LASA) is currently trading at 6.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lasa Supergenerics Limited is engaged in manufacturing, trading, and producing chemicals, pharmaceuticals, and veterinary APIs, with comprehensive capabilities in research, production, and marketing. The company specializes in catalyst chemistry and is among India's largest producers of anthelmintic and veterinary API products, with significant production capacity at its facilities in Maharashtra. Lasa's strategic amalgamation with Harishree Aromatics and Chemicals Pvt. Ltd. strengthens its manufacturing capabilities and market reach, approved by the National Company Law Tribunal in late 2022. The company has launched two new high-demand veterinary products and is expanding capacity at its Chiplun unit, aiming to capture significant market share globally. With a WHO Certificate of Good Manufacturing Practices, Lasa is positioned as a key player in the animal healthcare sector with robust global alliances.
Over the past 52 weeks, Lasa Supergenerics Ltd has traded between a low of ₹5.65 and a high of ₹14.14. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lasa Supergenerics Ltd has a market capitalization of approximately 33.62. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lasa Supergenerics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -2.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 33.62 Cr, Lasa Supergenerics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lasa Supergenerics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lasa Supergenerics Ltd is -2.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting to consider and approve unaudited Q1 FY27 results (quarter ended June 30, 2026) is scheduled for August 14, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
14.05 | 35 Cr | -1.51 | 4.11 | 0.00 | -117.84 | -25.84 | -37.84 | ||
31.20 | 34 Cr | -18.92 | 0.30 | 0.00 | -2.72 | -2.70 | -1.54 | ||
6.55 | 34 Cr | -2.03 | 0.68 | 0.00 | -26.30 | -22.21 | -24.96 | ||
39.45 | 33 Cr | 9.00 | 0.94 | 0.00 | 20.15 | 30.12 | 10.11 | ||
23.40 | 33 Cr | 5.56 | 0.88 | 0.00 | 15.82 | 19.17 | 11.89 | ||
10.15 | 32 Cr | 4.74 | 0.70 | 0.00 | 13.96 | 15.84 | 6.02 | ||
39.49 | 32 Cr | 15.36 | 3.28 | 0.00 | 25.62 | 29.29 | 8.47 | ||
| Median: 7 Co. | — | 23.40 | 33 Cr | 4.74 | 0.88 | 0.00 | 13.96 | 15.84 | 6.02 |
